As antibodies and ADC drugs become the backbone of innovative drugs, the level of intelligence in the production process is redefining the competitive boundaries of the industry. From "manufacturing" to "intelligent manufacturing" is not only a technological upgrade, but also a systematic change from process development, quality control to compliance implementation.

The complete schedule for the intelligent production of antibodies and ADC drugs was officially released today. The special session will gather practical experts in the field of biopharmaceutical production and technology, focusing on core issues such as the new paradigm of intelligent manufacturing driven by the integration of mechanisms and AI, the development of ADC processes and analysis methods, the reconstruction of digital process systems, and compliance implementation. It will deeply explore how intelligence can reshape the competitive landscape of the biopharmaceutical industry.

From July 22nd to 24th, at the Shanghai National Convention and Exhibition Center, we look forward to exploring the intelligent manufacturing future of antibody and ADC drug production with you.

Scan the code to register immediately
Early bird tickets are available for a limited time at a 25% discount!!

// Session Schedule //

Co-organized by:Hanbon Technology

09:00-11:40 / 23rd

09:00-09:05　Opening Remarks
Shuxiang Xu: Secretary-General, China Pharmaceutical Association of Plant Engineering (CPAPE)

09:05-09:30　Breaking the Black Box: A New Era of Biomanufacturing Driven by Mechanism-AI Integration
Kang Yun: Founder and CEO, Magic Mirror Biotech

09:30-09:45　ADC Process and Analytical Method Development
Wei Gong: General Manager of CMC Operations, Aton Bio, Henlius

09:45-10:00　TBD
Jun Ma: Deputy General Manager, Junshi Biosciences

10:00-10:15　AI for CMC: The Shift from Experience-Driven to Data-Driven
Hao Li: CMC Deputy General Manager, HUTCHMED (Shanghai)

10:15-10:30　Break

10:30-10:45　Phase-appropriate Analytical Method Lifecycle Management
Chao Liu: Senior Director of QC, Zai Lab

10:45-11:00　Digital-Intelligence Integration: Reconstructing the Process Development System for Bioculture Media
Yantao Wang: Chairman, Medium Bank

11:00-11:40　Panel Discussion: How Does Smart Manufacturing Reshape the Competitive Landscape of the Biopharmaceutical Industry?
Kang Zhou (Moderator): General Manager of Bio-macromolecule Division, Hanbon Technology
Xiaoqiang Kang: Founder, Chairman and CEO, Leads Biolabs
Jian Zhang: Acting CEO, BioDlink
Weijun Wang: Senior Vice President of Biology, Zelgen
Mingxin Li: CEO, CellPlus Bio
Xinyi Gu: CFO, EpimAb
Qingguo Song: Vice President, Kindos Pharma